权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Synthetic biology tools for scalable production of medicinal plant terpenes

用于药用植物萜烯大规模生产的合成生物学工具

基本信息

批准号：
10653942
负责人：
JAY D KEASLING
金额：
$ 66.17万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-15 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10653942
关键词：
Acceleration Address Alleles Anabolism Antineoplastic Agents Artemisinins Candidate Disease Gene Catalysis Cell Culture Techniques Chemicals Chemistry Clinical Complex Coupling Cytochrome P450 Cytochromes Development Digoxin Diterpenes Drug usage Engineering Enzyme Tests Enzymes Equilibrium Etoposide Gene Expression Profiling Genes Genome Health Human Investigation Lead Malignant Neoplasms Medicinal Plants Medicine Metabolic Pathway Metabolism Mining Narrative Medicine Natural Products Nature Nicotiana Outcome Oxidation-Reduction Oxidative Stress Oxidoreductase Paclitaxel Pathway interactions Plants Podophyllum Production Protein Engineering Proteins Role Route Saccharomyces cerevisiae Series Sonic Hedgehog Pathway Source Specificity Structure Taxus Terpenes Testing Therapeutic Therapeutic Uses Uncertainty Variant Veratrum Work Yeasts analog biological adaptation to stress candidate identification chemical synthesis clinical candidate combinatorial cyclopamine design drug candidate electron donor gene discovery human disease improved inhibitor manufacturing scale-up novel novel strategies scaffold sesterterpenes synthetic biology taxadiene therapeutic candidate tool transcriptomics

项目摘要

PROJECT SUMMARY/ABSTRACT Plant terpenes are a critical source of clinically approved drugs and clinical candidates, yet very few complete biosynthetic pathways have been characterized. Due to the lack of efficient chemical synthesis routes, many complex plant natural product scaffolds including terpenes are currently still isolated from the producing plant or plant cell culture and then converted to a clinically-used drug by semisynthetic routes (e.g. digoxin and taxol on the 2015 WHO list of essential medicines). Lack of information regarding terpene biosynthetic pathways severely limits the use of promising new approaches to produce plant molecules in heterologous hosts (e.g. yeast strains that make artemisinin), as well as the intriguing possibility of engineering the biosynthetic pathways to access analogs and non-natural derivatives with greater efficacy. Given the critical role of medicinal plant terpenes in human health and utility of biosynthetic genes, we propose here systematic discovery of key medicinal plant terpene biosynthesis pathways, taxol and cyclopamine, and the engineering of yeast strains for scalable production. Classically, the discovery of plant pathways has been slower and more painstaking than bacterial pathways; however, our team has demonstrated two approaches that greatly accelerates identification of complete biosynthetic routes: (1) rapid combinatorial testing of enzymes in a N. benthamiana heterologous host, and (2) transcriptional profiling and co-expression analysis to identify pathway genes. This approach enabled the discovery of six enzymes that complete the pathway to the etoposide aglycone from the unsequenced medicinal plant Podophyllum in a matter of months and has also led to the discovery of numerous plant terpene pathways including a novel class of sesterterpenes. In this proposal, we have prioritized pathways for valuable medicinal plant terpenes that are notoriously difficult to access: the clinically used anticancer agent taxol and the clinical candidate cyclopamine. These compounds are representative medicinal plant terpenes that will be used to demonstrate the broad utility of our discovery and yeast engineering approach that can be applied for accessing many of the other >100,000 different plant terpenes in nature. In addition to yeast strains that produce these highly valuable plant terpenes, a major outcome of this work will be broadly applicable yeast synthetic biology tools for efficient production of multiple cytochromes P450s in series which represents a major bottleneck for efficient transfer of plant pathways to yeast heterologous hosts.

项目总结/摘要植物萜烯是临床批准的药物和临床候选物的重要来源，但很少有完整的植物萜烯。生物合成途径已被表征。由于缺乏有效的化学合成路线，许多包括萜烯的复杂的植物天然产物支架目前仍从生产植物中分离或植物细胞培养，然后通过半合成途径转化为临床使用的药物（例如地高辛和紫杉醇 2015年世界卫生组织基本药物清单）。缺乏有关萜类生物合成途径的信息严重限制了在异源宿主（例如，制造青蒿素的酵母菌株），以及设计生物合成青蒿素的有趣可能性。获得类似物和非天然衍生物的途径具有更大的功效。考虑到药用植物萜烯在人类健康和生物合成基因的效用，我们在这里提出系统发现了关键的药用植物萜类生物合成途径，紫杉醇和环巴胺，工程化酵母菌株以用于可规模化生产。传统上，植物途径的发现比细菌途径更慢，更费力;然而，我们的团队已经证明了两种方法，这大大加速了完整生物合成途径的鉴定：（1）快速组合测试酶在N.本塞姆氏异源宿主，和（2）转录谱分析和共表达分析，识别通路基因。这种方法使六种酶的发现成为可能，这些酶完成了通往蛋白质的途径。在几个月的时间里，从未测序的药用植物鬼臼属中提取出依托泊苷元，发现了许多植物萜途径，包括一类新的二倍半萜。在这我们已经优先考虑了有价值的药用植物萜类化合物的途径，这些萜类化合物是出了名的难以分离的。获取：临床使用的抗癌药紫杉醇和临床候选药物环巴胺。这些化合物是代表性的药用植物萜烯，将用于证明我们的发现的广泛用途和酵母工程的方法，可用于访问许多其他> 100，000不同的植物自然界中的萜烯。除了生产这些高价值植物萜烯的酵母菌株外，这项工作的成果将是广泛适用的酵母合成生物学工具，用于高效生产多种细胞色素P450系列，这代表了植物途径有效转移到酵母异源宿主